Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO.

Jeremy S. Abramson, Matthew Ku, Mark Hertzberg, Christopher P. Fox, Charles Herbaux, Dok Hyun Yoon, Won Seog Kim, Huilai Zhang, Haifaa Abdulhaq, William Townsend, Estefania Mulvihill, Victor Orellana-Noia, Richard Ta, Huang Huang, Martine Kallemeijn, Anton Belousov, Alessia Bottos, Linda Lundberg, Gareth P. Gregory. Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO. Journal of Clinical Oncology. 2025 Jun 1; 43(16_suppl):7015-7015.